BPH
MCID: PRS129
MIFTS: 49

Prostatic Hyperplasia, Benign (BPH)

Categories: Endocrine diseases, Nephrological diseases

Aliases & Classifications for Prostatic Hyperplasia, Benign

MalaCards integrated aliases for Prostatic Hyperplasia, Benign:

Name: Prostatic Hyperplasia, Benign 57
Benign Prostatic Hyperplasia 55 17 72
Prostatic Hyperplasia 72
Bph 57

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant


HPO:

32
prostatic hyperplasia, benign:
Inheritance autosomal dominant inheritance
Onset and clinical course infantile onset


Classifications:



External Ids:

OMIM 57 600082
MedGen 42 C1704272
UMLS 72 C1704272 C2937421

Summaries for Prostatic Hyperplasia, Benign

OMIM : 57 Benign prostatic hyperplasia (BPH) refers to the nonmalignant growth of the prostate gland, and is histologically defined as hyperplasia of the prostate gland. BPH is an age-related phenomenon in men beginning at about age 40 years. BPH may result in prostatic enlargement and clinical symptoms most commonly affecting the lower urinary tract. These symptoms may be obstructive, including hesitancy, weak flow, and urinary retention, or irritative, including increased frequency and urgency. However, not all men with histologic BPH will develop prostatic enlargement or urinary symptoms (review by Roehrborn, 2005). (600082)

MalaCards based summary : Prostatic Hyperplasia, Benign, also known as benign prostatic hyperplasia, is related to prostatic hypertrophy and prostatic adenoma, and has symptoms including prostatism An important gene associated with Prostatic Hyperplasia, Benign is CDKN2B-AS1 (CDKN2B Antisense RNA 1), and among its related pathways/superpathways are Transcription Androgen Receptor nuclear signaling and Metabolism of steroid hormones. The drugs Scopolamine and Saw palmetto have been mentioned in the context of this disorder. Affiliated tissues include prostate, testes and smooth muscle, and related phenotype is benign prostatic hyperplasia.

Wikipedia : 75 Benign prostatic hyperplasia (BPH), also called prostate enlargement, is a noncancerous increase in size... more...

Related Diseases for Prostatic Hyperplasia, Benign

Diseases related to Prostatic Hyperplasia, Benign via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 305)
# Related Disease Score Top Affiliating Genes
1 prostatic hypertrophy 32.9 KLK3 AR ADRA1A
2 prostatic adenoma 32.3 SRD5A1 KLK3
3 androgenic alopecia 30.8 SHBG KLK3 AR
4 estrogen excess 30.5 SHBG ESR2
5 impotence 30.3 SRD5A1 SHBG PDE5A KLK3
6 suppression of tumorigenicity 12 30.3 KLK3 FOLH1 AR
7 sexual disorder 30.3 SHBG PDE5A KLK3
8 alopecia, androgenetic, 1 30.1 SRD5A2 SRD5A1 SHBG AR
9 gynecomastia 30.1 SHBG KLK3 AR
10 polycystic ovary syndrome 30.0 SRD5A1 SHBG CYP17A1
11 prostate disease 30.0 SRD5A1 SERPINA3 KLK3 FOLH1 CYP17A1 CDKN2B-AS1
12 breast disease 29.8 SHBG KLK3 ESR2
13 pseudohermaphroditism 29.7 SRD5A2 CYP17A1 AR
14 hypospadias 29.4 SRD5A2 SRD5A1 CYP17A1 AR
15 prostatitis 29.3 KLK3 ADRA1A
16 prostate cancer 25.2 UCA1 SRD5A2 SRD5A1 SHBG SERPINA3 KLK3
17 adenocarcinoma 10.5
18 pulmonary alveolar microlithiasis 10.5
19 low compliance bladder 10.4
20 neurogenic bladder 10.4
21 alopecia 10.4
22 47, xxy 10.4 SHBG AR
23 vaginitis 10.4 ESR2 AR
24 insulin-like growth factor i 10.4
25 hydronephrosis 10.4
26 kidney disease 10.4
27 b-cell lymphoma 10.4
28 gender identity disorder 10.3 ESR2 AR
29 5-alpha reductase deficiency 10.3 SRD5A2 SRD5A1
30 proteasome-associated autoinflammatory syndrome 1 10.3
31 chronic kidney disease 10.3
32 complete androgen insensitivity syndrome 10.3 SHBG AR
33 pure autonomic failure 10.3
34 testicular germ cell cancer 10.3 ESR2 AR
35 hermaphroditism 10.3 SRD5A2 AR
36 non-alcoholic fatty liver disease 10.3
37 bacteriuria 10.3
38 dyspepsia 10.3
39 liver disease 10.3
40 liver cirrhosis 10.3
41 fatty liver disease 10.3
42 psychosexual disorder 10.3 SHBG PDE5A
43 urethral stricture 10.2
44 sebaceous gland disease 10.2 SHBG AR
45 androgen insensitivity, partial 10.2 SRD5A1 SHBG AR
46 diabetes mellitus, noninsulin-dependent 10.2
47 transitional cell carcinoma 10.2
48 withdrawal disorder 10.2 KLK3 AR
49 pulmonary disease, chronic obstructive 10.2
50 inguinal hernia 10.2

Graphical network of the top 20 diseases related to Prostatic Hyperplasia, Benign:



Diseases related to Prostatic Hyperplasia, Benign

Symptoms & Phenotypes for Prostatic Hyperplasia, Benign

Human phenotypes related to Prostatic Hyperplasia, Benign:

32
# Description HPO Frequency HPO Source Accession
1 benign prostatic hyperplasia 32 HP:0008711

Symptoms via clinical synopsis from OMIM:

57
G U:
benign prostatic hyperplasia

Misc:
early age of onset

Clinical features from OMIM:

600082

UMLS symptoms related to Prostatic Hyperplasia, Benign:


prostatism

Drugs & Therapeutics for Prostatic Hyperplasia, Benign

Drugs for Prostatic Hyperplasia, Benign (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 209)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Scopolamine Approved, Investigational Phase 4 6533-68-2, 51-34-3 5184
2
Saw palmetto Approved, Experimental, Investigational Phase 4
3
Silodosin Approved Phase 4 160970-54-7
4
Finasteride Approved Phase 4 98319-26-7 57363
5
Sodium citrate Approved, Investigational Phase 4 68-04-2
6
carbamide peroxide Approved Phase 4 124-43-6
7
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
8
Methyltestosterone Approved Phase 4 58-18-4 6010
9
Testosterone enanthate Approved Phase 4 315-37-7 9416
10
Testosterone Approved, Experimental, Investigational Phase 4 481-30-1, 58-22-0 6013 10204
11
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
12
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
13
Tranexamic Acid Approved Phase 4 1197-18-8 5526
14
Dihydrotachysterol Approved Phase 4 67-96-9 5311071 5281010
15
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
16
Fesoterodine Approved Phase 4 286930-03-8, 286930-02-7 6918558
17
Selegiline Approved, Investigational, Vet_approved Phase 4 14611-51-9 5195 26757
18
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
19
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
20
Mirabegron Approved Phase 4 223673-61-8 9865528
21
Methoxyflurane Approved, Investigational, Vet_approved Phase 4 76-38-0 4116
22
Dutasteride Approved, Investigational Phase 4 164656-23-9 152945 6918296
23
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
24
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
25
Aspartic acid Approved, Nutraceutical Phase 4 56-84-8 5960
26
Cimetropium Experimental, Investigational Phase 4 150521-16-7
27 Naftopidil Investigational Phase 4 57149-07-2
28
Dihydrotestosterone Illicit, Investigational Phase 4 521-18-6 10635
29
Fibrinolysin Investigational Phase 4 9004-09-5
30 Cola Phase 4
31 Anticonvulsants Phase 4
32 Bromides Phase 4
33 Autonomic Agents Phase 4
34 Antiemetics Phase 4
35 Gastrointestinal Agents Phase 4
36 Mydriatics Phase 4
37 Butylscopolammonium Bromide Phase 4
38 Anti-Infective Agents Phase 4
39 Saw palmetto extract Phase 4
40 Cholinergic Agents Phase 4
41 Platelet Aggregation Inhibitors Phase 4
42 calcium channel blockers Phase 4
43 Calcium, Dietary Phase 4
44 Muscarinic Antagonists Phase 4
45 Solifenacin succinate Phase 4 242478-38-2
46 Cholinergic Antagonists Phase 4
47 Sildenafil Citrate Phase 4 171599-83-0
48 Citrate Phase 4
49 Mitogens Phase 4
50 Endothelial Growth Factors Phase 4

Interventional clinical trials:

(show top 50) (show all 523)
# Name Status NCT ID Phase Drugs
1 Clinical Pilot Trial on the Influence of a Saw Palmetto Berry Preparation on Sexual Functions in Patients With Benign Prostatic Hyperplasia Unknown status NCT01021267 Phase 4 Saw palmetto berry extract
2 Comparison Between Alpha Blocker Monotherapy and 5-alpha-reductase Inhibitor Monotherapy Following Combination Therapy in Benign Prostatic Hyperplasia Unknown status NCT01301599 Phase 4 combination therapy;alpha blocker monotherapy;5 alpha reductase inhibitor monotherapy
3 Efficacy and Safety of Naftopidil in Patient With Neurogenic Lower Urinary Tract Dysfunction Not Caused by Benign Prostatic Hyperplasia Unknown status NCT02034604 Phase 4 Naftofidil;Tamsulosin
4 A Prospective Multicenter Randomized Study Comparing Photoselective Vaporization of the Prostate With the GreenLight XPS™ Laser System and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Hyperplasia (The Goliath Study) Unknown status NCT01218672 Phase 4
5 Switch Study: Are There Any Measurable Differences When Switching Patients on Finasteride Therapy to Dutasteride? Unknown status NCT00690950 Phase 4 Dutasteride
6 Kinetics of the Finasteride Prostate Induced Apoptosis Unknown status NCT00130767 Phase 4 finasteride
7 Usefulness Of Flospan As A Premedication For Colonoscopy : A Randomized Double Blind Controlled Trial Unknown status NCT01842932 Phase 4 Phloroglucin;Cimetropium bromide;Placebo
8 Post-Marketing Study Using PROLIEVE® for the Treatment of Benign Prostatic Hyperplasia (BPH) Unknown status NCT02021032 Phase 4
9 Prospective Non-randomized Trial Comparing Holmium Laser Enucleation of the Prostate Versus Greenlight Laser Photoselective Vaporization of the Prostate in Treating Benign Prostate Hyperplasia in Patients With Bleeding Tendency Unknown status NCT02293759 Phase 4
10 Evaluation of Solifenacin in the Treatment of OAB Symptoms in Patients Who Have Successfully Undergone GreenLight Photoselective Vaporization of the Prostate (PVP)for the Treatment of Clinically Significant Benign Prostate Hyperplasia (BPH) Unknown status NCT00826527 Phase 4 Solifenacin PO
11 Does Hyoscine N-butylbromide Administered During Colonoscopy Increase the Polyp Detection Rate? a Randomized, Single Center, Double Blind, Placebo-controlled Study Unknown status NCT01609855 Phase 4 Hyoscine Butyl Bromide 20mg/2 ml i.v.;Saline 2 ml i.v.
12 Prostatic Artery Embolization Versus 532 nm Green Light Laser Photoselective Vaporization of the Prostate for Treating Catheter-Dependent Patients With Benign Prostatic Hyperplasia: A Randomized Controlled Clinical Study Unknown status NCT02006303 Phase 4
13 Behavior and Exercise Versus Drug Treatment in Men With Nocturia Unknown status NCT00824200 Phase 4 tamsulosin (alpha-adrenergic antagonist medication);placebo
14 Comparation the Effect of C-LMA and I-gel in Regurgitation and Postoperative Complications Unknown status NCT01876836 Phase 4
15 A Multicenter, Randomized, Double-blind, Clinical Study to Investigate the Efficacy and Safety of Treatment With Tamsulosin 0.2mg Mono and Tamsulosin 0.2mg, Finasteride 5mg Combination Therapy in Patients With LUTS/BPH Unknown status NCT01736033 Phase 4 Tamsulosin;Finasteride;Placebo
16 Low Dose, Low Concentration Different Baricity Bupivacaine for Transuretral Prostatectomy. Unknown status NCT01861041 Phase 4 Heavy Bupivacaine;Isobaric Bupivacaine
17 Comparison of the Efficacy and Safety of Combination Treatment With Doxazosin Plus TolterodineSR 2 mg vs Doxazosin Plus TolterodineSR 4 mg in Men With an OAB/BPO: Randomized Controlled Study" Unknown status NCT00922506 Phase 4 doxazosin plus tolterodine SR
18 Ejaculatory Sparing vs. Non-ejaculatory Sparing GreenLightTM Laser Photoselective Vaporization of the Prostate (PVP): A Randomized Double Blind Sexual and Urodynamic Assessment Unknown status NCT02749604 Phase 4
19 The Effect of KTP (Potassium-titanyl-phosphate) Green Light Prostatectomy (180W) Compared With Open Prostatectomy When Treating Benign Prostatic Hyperplasia, a Prospective Randomized Study Completed NCT02072499 Phase 4
20 A 12-week, Open Label, Multi-center Study to Investigate the Efficacy and Safety of a α1A Adrenoceptor Selective Antagonist Silodosin on Urinary Disturbance Associated With Benign Prostatic Hyperplasia Completed NCT01259531 Phase 4 Silodosin
21 PERMIXON® 160 mg Hard Capsule Versus Placebo in the Treatment of Symptomatic Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia Completed NCT02121613 Phase 4 Permixon® 160 mg;Tamsulosine LP;Placebo matching Permixon® 160 mg;Placebo matching Tamsulosine LP
22 An Open-Label Randomized Phase 4 Study of Greenlight XPS Laser Versus BiVAP Saline Vaporization of the Prostate in Men With Symptomatic Benign Prostatic Hyperplasia Completed NCT01500057 Phase 4
23 A Randomized, Double-blind, Placebo-controlled Study to Assess the Effect of Tamsulosin OCAS 0.4 mg Tablets, Once Daily on Nocturia, Compared to Placebo, in Patients With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia Completed NCT00379067 Phase 4 Tamsulosin OCAS;Placebo
24 Evaluation of the Effect of 10 mg Alfuzosin (Alfetim Uno®) o. d. in Patients Presenting Low-Urinary Tract Symptoms Completed NCT00637715 Phase 4 Alfuzosin
25 Study of the Outcome of Patients With Lower Urinary Symptoms Suggestive of Benign Prostatic Hyperplasia and Treated With Alfuzosin 10 mg Once Daily for 3 Months in China Completed NCT00280605 Phase 4 Alfuzosin
26 A Forty-Five Day, Open-label Study of the Symptomatic Relief Effects of FLOMAX® Capsules 0.4 mg Daily in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia Completed NCT02244242 Phase 4 Tamsulosin hydrochloride
27 An Eleven-Week, Open-Label, Randomized, Multicenter, Parallel-Design, Placebo Lead-in Study of FLOMAX® Capsules, 0.4 mg Daily Versus HYTRIN® Capsules, 5 mg (With Titration) Daily in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia Completed NCT02244255 Phase 4 FLOMAX® capsules;Ascending doses of HYTRIN® capsules
28 A Post-Marketing Clinical Study of LY450190 (Combined With Alpha1 Blocker Treatment) Completed NCT02431754 Phase 4 Tadalafil;Placebo;Alpha1 Blocker
29 A Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Design Clinical Trial to Evaluate the Efficacy and Safety of Naftopidil in Male Patients With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia Completed NCT01922375 Phase 4 Naftopidil
30 Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin 10mg Once Daily (XATRAL 10mg OD), Open, 24-week Study. Completed NCT00401661 Phase 4 Alfuzosin
31 Apoptosis and Expression of Neovascularization-related Factors in Human Prostate Tissue After Administration of Dutasteride Completed NCT00880672 Phase 4 dutasteride
32 BLADDER (BPH, LUTS And Detrusor: Dual Effect Research) Study: A Multicentre, Double-blind, Randomised, Parallel Group, Placebo-controlled Study, Aimed at Characterising the Effect of Tamsulosin on Lower Urinary Tract Symptoms (LUTS) and Detrusor Motor Activity in Patients Affected by Benign Prostatic Hyperplasia (BPH) and Storage Urinary Symptoms Completed NCT02245490 Phase 4 Tamsulosin HCl controlled release capsules;Matching placebo capsule
33 Effectiveness and Safety of Silodosin in the Treatment of LUTS in Patients With Benign Prostatic Hyperplasia: a European Phase IV Clinical Study. The Silodosin in Real-life Evaluation Study Completed NCT01757769 Phase 4 Silodosin
34 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study of Solifenacin Succinate as Add-on Therapy for Overactive Bladder (OAB) Symptoms in Men Treated for Benign Prostatic Hyperplasia (BPH) With Tamsulosin Hydrochloride Completed NCT00771394 Phase 4 Tamsulosin hydrochloride;Solifenacin succinate
35 An Open-label, Prospective Interventional Study of the Tolerability and Efficacy of Oral Harnalidge® OCAS® (Tamsulosin) 0.4 mg in Patients Who Are Unsatisfied With the Treatment of Tamsulosin 0.2 mg Completed NCT02180789 Phase 4 Tamsulosin OCAS
36 A Multi-center, Prospective, Open-label, Single-arm, 12-weeks, Phase IV Trial to Evaluate the Efficacy and Safety of Silodosin on Nocturia for Patients With Benign Prostatic Hyperplasia Completed NCT02106182 Phase 4 Silodosin
37 A Randomized, Open-label, Parallel-group Study, to Assess the Pharmocodynamic Effect on Dihydrotestosterone Regulated Gene Expression, Longitudinally and in a Dose Dependent Manner, of 0.5mg and 3.5mg Dutasteride Administered Orally Once Daily, for One Year in Men With Symptomatic Benign Prostatic Hyperplasia and During a Two Month Period Between Baseline and Radical Prostatectomy in Men With Biopsy-proven, Clinically Localized Prostate Cancer Completed NCT00375765 Phase 4 Dutasteride
38 ALEX-XL: Alfuzosin XL-Lower Urinary Tract Symptoms Efficacy and Sexuality Study Completed NCT00575913 Phase 4 Alfuzosin
39 A Prospective Clinical Study for GreenLight HPS in the Treatment of Obstructive Benign Prostatic Hyperplasia (BPH) Completed NCT00465101 Phase 4
40 A Multicenter, Randomized, Parallel Group, Double-Blind, Placebo-Controlled Flexible Dose Study With and Open-Label Extension to Assess the Efficacy and Safety of Viagra (Sildenafil Citrate) in the Treatment of Men With Erectile Dysfunction (ED) and Concomitant Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH) in the United States Completed NCT00143221 Phase 4 Viagra;Placebo
41 A Phase 4, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Mirabegron in Japanese and Korean Male Patients With Overactive Bladder Under Treatment With the α-Blocker Tamsulosin for Benign Prostatic Hyperplasia Completed NCT02656173 Phase 4 Mirabegron;Placebo;Tamsulosin
42 A Prospective Evaluation of the GreenLight Model 120 Laser System for the Treatment of Benign Prostatic Hyperplasia Completed NCT00364585 Phase 4
43 Dutasteride (0.5mg) Once Daily for One Year and Tamsulosin (0.4mg) Once Daily for 3 Months, Followed by Counseling on Flex Dose Tamsulosin as Needed on Improvement of Symptoms and Outcome in Men With Moderate to Severe Symptomatic BPH Completed NCT00701779 Phase 4 Tamsulosin
44 Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin 10mg Once Daily (XATRAL OD 10mg), Open, 24-week Study Completed NCT00486785 Phase 4 Alfuzosin
45 MICTUS (Multicentre Investigation to Characterise the Effect of Tamsulosin on Urinary Symptoms): A Multicentre, Double-blind, Randomised, Parallel Group Study, Aimed at Characterising the Effect of Tamsulosin, an Uroselective α1- Receptor Blocking Agent, on the Urological Symptoms and Their Impact on General Health Status and Quality of Life in Outpatients Affected by Symptomatic Benign Prostatic Hyperplasia: Comparison With Finasteride. Completed NCT02244229 Phase 4 Tamsulosin;Finasteride;Placebo
46 Assessment of Prostatic Tissue Concentration of Ertapenem After a Pre-operative Administration Completed NCT02041767 Phase 4 Ertapenem
47 The Long Term Effects of Alfuzosin (Xatral XL) in LUTS/BPH Patients: Evaluation of Symptom-specific Goal Achievement According to Symptom Improvement, Bladder Outlet Obstruction Grade and Bladder Contractility Completed NCT00836823 Phase 4 Alfuzosin
48 A Prospective, Open-Labeled Trial of the Safety and Efficacy of Doxazosin GITS in Patients With Benign Prostate Hyperplasia Completed NCT00648323 Phase 4 Doxazosin mysylate GITS
49 A Prospective Randomized Clinical Trial of Bipolar vs Monopolar Transurethral Resection of the Prostate (TURP) Completed NCT00199550 Phase 4
50 Testosterone Replacement and Dutasteride Effectiveness (TRADE) Completed NCT00194675 Phase 4 Dutasteride;Testosterone gel;Placebo dutasteride

Search NIH Clinical Center for Prostatic Hyperplasia, Benign

Inferred drug relations via UMLS 72 / NDF-RT 51 :


alfuzosin
Alfuzosin
Doxazosin
Doxazosin Mesylate
Dutasteride
Dutasteride
Finasteride
Finasteride
Leuprolide
Leuprolide Acetate
Prazosin
Prazosin
Prazosin hydrochloride
Saw palmetto extract
silodosin
Silodosin
Tadalafil
tamsulosin
Tamsulosin
Tamsulosin hydrochloride
Terazosin
Terazosin
terazosin hydrochloride

Genetic Tests for Prostatic Hyperplasia, Benign

Anatomical Context for Prostatic Hyperplasia, Benign

MalaCards organs/tissues related to Prostatic Hyperplasia, Benign:

41
Prostate, Testes, Smooth Muscle, Bone, Kidney, Endothelial, Liver

Publications for Prostatic Hyperplasia, Benign

Articles related to Prostatic Hyperplasia, Benign:

(show top 50) (show all 13173)
# Title Authors PMID Year
1
A preliminary study of JM-27: a serum marker that can specifically identify men with symptomatic benign prostatic hyperplasia. 38 8
17222644 2007
2
Benign prostatic hyperplasia: an overview. 38 8
16985902 2005
3
Genetic susceptibility of benign prostatic hyperplasia. 38 8
7515446 1994
4
Medications and surgical interventions for benign prostatic hyperplasia are potential confounders of prostate-specific antigen. 9 38
20467844 2010
5
Between-subject variations of transition zone epithelial volume and serum PSA levels in men with benign prostatic hyperplasia. 9 38
19690867 2010
6
Expression of toll-like receptor-9 is increased in poorly differentiated prostate tumors. 9 38
20054821 2010
7
Investigating contamination of phytotherapy products for benign prostatic hyperplasia with alpha-blockers and 5alpha-reductase inhibitors. 9 38
20303529 2010
8
Extracellular matrix associated protein CYR61 is linked to prostate cancer development. 9 38
20172544 2010
9
Vitamin D receptor agonists target static, dynamic, and inflammatory components of benign prostatic hyperplasia. 9 38
20398021 2010
10
Serum level of clusterin and its density in men with prostate cancer as novel biomarkers reflecting disease extension. 9 38
19854485 2010
11
Silodosin for benign prostatic hyperplasia. 9 38
20071497 2010
12
Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract. 9 38
19796053 2010
13
Prostasin regulates iNOS and cyclin D1 expression by modulating protease-activated receptor-2 signaling in prostate epithelial cells. 9 38
19670249 2009
14
DD3(PCA3) gene expression in cancer and prostatic hyperplasia. 9 38
20003831 2009
15
Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery. 9 38
19757985 2009
16
Longer (TA)n repeat but not A49T and V89L polymorphisms in SRD5A2 gene may confer prostate cancer risk in South Indian men. 9 38
19443907 2009
17
Effect of Tadalafil on prostate haemodynamics: preliminary evaluation with contrast-enhanced US. 9 38
19697101 2009
18
TRPV6 alleles do not influence prostate cancer progression. 9 38
19857260 2009
19
Men's sexual health: evaluating the effectiveness of print- and PDA-based CME. 9 38
19453917 2009
20
Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia? 9 38
19239452 2009
21
Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia. 9 38
19428074 2009
22
Elocalcitol, a vitamin D3 analog for the potential treatment of benign prostatic hyperplasia, overactive bladder and male infertility. 9 38
19517319 2009
23
CYP17 gene polymorphism and its association in north Indian prostate cancer patients. 9 38
19443382 2009
24
Effect of discontinuation of 5alpha-reductase inhibitors on prostate volume and symptoms in men with BPH: a prospective study. 9 38
19193422 2009
25
Effects of chronic treatment with vardenafil, a phosphodiesterase 5 inhibitor, on female rat bladder in a partial bladder outlet obstruction model. 9 38
19021615 2009
26
The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways. 9 38
19107880 2009
27
[Expression of estrogen receptor beta in benign prostatic hyperplasia complicated by chronic prostatitis]. 9 38
19472903 2009
28
[Medical combination therapy in LUTS suggestive of BPH]. 9 38
19212753 2009
29
Cyr61 is up-regulated in prostate cancer and associated with the p53 gene status. 9 38
19180570 2009
30
The role of prostate specific membrane antigen and pepsinogen C tissue expression as an adjunctive method to prostate cancer diagnosis. 9 38
19084862 2009
31
Influence of inflammation and aging on macrophage inhibitory cytokine-1 gene expression in rat ventral prostate. 9 38
18929399 2009
32
The role of combination medical therapy in benign prostatic hyperplasia. 9 38
19002123 2008
33
Oral phosphodiesterase type 5 inhibitors: nonerectogenic beneficial uses. 9 38
18761597 2008
34
Celecoxib for treatment of nocturia caused by benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled study. 9 38
18692876 2008
35
Association between 5-alpha reductase inhibition and risk of hip fracture. 9 38
18840839 2008
36
Joint effects of inflammation and androgen metabolism on prostate cancer severity. 9 38
18566991 2008
37
Shorter CAG repeats in androgen receptor and non-GG genotypes in prostate-specific antigen loci are associated with decreased risk of benign prostatic hyperplasia and prostate cancer. 9 38
18495332 2008
38
The effect of 5 alpha-reductase inhibitors on erectile function. 9 38
18421068 2008
39
Serum vascular endothelial growth factor C level in patients with prostate cancer and benign prostatic hyperplasia. 9 38
18773737 2008
40
Methylation-specific sequencing of GSTP1 gene promoter in circulating/extracellular DNA from blood and urine of healthy donors and prostate cancer patients. 9 38
18837951 2008
41
Combination 5-alpha-reductase inhibitors and alpha-blockers for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. 9 38
18765128 2008
42
Protease-activated receptor-1 upregulates fibroblast growth factor 7 in stroma of benign prostatic hyperplasia. 9 38
18386288 2008
43
Immunohistochemical expression of topoisomerase II alpha and Her-2/neu in prostatic carcinoma and benign prostatic hyperplasia. 9 38
20029472 2008
44
Interactive spaced education versus web based modules for teaching urology to medical students: a randomized controlled trial. 9 38
18423715 2008
45
Serum sex steroids, gonadotrophins and sex hormone-binding globulin in prostatic hyperplasia. 9 38
18500180 2008
46
A role for the androgen-receptor in clinically localized and advanced prostate cancer. 9 38
18471792 2008
47
5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction. 9 38
18471794 2008
48
Relationship of prostate-specific antigen and prostate volume in Korean men with biopsy-proven benign prostatic hyperplasia. 9 38
18342171 2008
49
The role of estrogens and estrogen receptors in normal prostate growth and disease. 9 38
18093629 2008
50
Doxazosin in the current treatment of hypertension. 9 38
18312163 2008

Variations for Prostatic Hyperplasia, Benign

Expression for Prostatic Hyperplasia, Benign

Search GEO for disease gene expression data for Prostatic Hyperplasia, Benign.

Pathways for Prostatic Hyperplasia, Benign

GO Terms for Prostatic Hyperplasia, Benign

Cellular components related to Prostatic Hyperplasia, Benign according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell body fiber GO:0070852 8.32 SRD5A1

Biological processes related to Prostatic Hyperplasia, Benign according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 steroid metabolic process GO:0008202 9.69 SRD5A2 SRD5A1 CYP17A1
2 cell-cell signaling GO:0007267 9.67 SRD5A2 ESR2 AR ADRA1A
3 male gonad development GO:0008584 9.63 SRD5A2 SRD5A1 AR
4 positive regulation of cardiac muscle hypertrophy GO:0010613 9.55 PDE5A ADRA1A
5 male genitalia development GO:0030539 9.54 SRD5A2 SRD5A1
6 androgen metabolic process GO:0008209 9.52 SRD5A2 SRD5A1
7 regulation of systemic arterial blood pressure GO:0003073 9.49 KLK3 AR
8 progesterone metabolic process GO:0042448 9.43 SRD5A1 CYP17A1
9 cellular response to testosterone stimulus GO:0071394 9.4 SRD5A1 AR
10 steroid biosynthetic process GO:0006694 9.33 SRD5A2 SRD5A1 CYP17A1
11 response to testosterone GO:0033574 9.26 SRD5A1
12 hypothalamus development GO:0021854 9.18 SRD5A1
13 androgen biosynthetic process GO:0006702 9.13 SRD5A2 SRD5A1 CYP17A1
14 response to follicle-stimulating hormone GO:0032354 9.02 SRD5A1
15 female genitalia development GO:0030540 8.96 SRD5A1
16 sex differentiation GO:0007548 8.92 SRD5A2 SRD5A1 CYP17A1 AR

Molecular functions related to Prostatic Hyperplasia, Benign according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity, acting on the CH-CH group of donors GO:0016627 9.37 SRD5A2 SRD5A1
2 androgen binding GO:0005497 9.32 SHBG AR
3 cholestenone 5-alpha-reductase activity GO:0047751 9.26 SRD5A2 SRD5A1
4 3-oxo-5-alpha-steroid 4-dehydrogenase activity GO:0003865 8.96 SRD5A2 SRD5A1
5 amide binding GO:0033218 8.85 SRD5A1
6 steroid binding GO:0005496 8.8 SHBG ESR2 AR

Sources for Prostatic Hyperplasia, Benign

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....